HAMPTON, N.J., Jan. 7, 2014 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO, Daniel Tasse, will present at the 2014 Biotech Showcase™ conference. Mr. Tasse's presentation will be given on Tuesday, January 14, 2014 at 2:30 p.m. PST in the Hearst Room on the third floor of the Parc 55 Wyndham San Francisco Union Square Hotel in San Francisco, CA.
About Ikaria, Inc.
Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings. The Company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. Ikaria, alone or through partners, also markets the INOMAX therapy package in Puerto Rico, Canada, Australia, Mexico and Japan. Ikaria also has a number of cardiopulmonary development programs that are at the intersection of drugs and devices. These include inhaled nitric oxide via pulsed delivery which is being investigated for pulmonary arterial hypertension (PAH) and for chronic obstructive pulmonary disease (COPD), and the Bioabsorbable Cardiac Matrix device, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with research facilities in North Brunswick, NJ and Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI. Please visit www.ikaria.com.
SOURCE Ikaria, Inc.